MaxCyte FY 2024: revenue $38.6M, down 6%; diluted EPS −$0.39

Key figures from this report

These are the numbers MaxCyte reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$38.6M−6% from $41.3M in FY 202310-K income statement, on EDGAR
2. Net income−$41.1MAgainst −$37.9M in FY 202310-K income statement, on EDGAR
3. Diluted EPS−$0.39Against −$0.37 in FY 202310-K income statement, on EDGAR
4. Cash and cash equivalents$27.9M−40% from $46.5M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations−$27.6MAgainst −$21.7M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables